Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsDowngradesPrice Target
Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.
Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.